核心提示：诺华（Novartis）近日公布了2项关键性国际3期研究的数据，结果显示：在6岁至18岁以下的中度至重度斑块型银屑病儿童和青少年患者中，Cosentyx（中文商品名：可善挺，通用名：secukinumab，司库奇尤单抗，俗称“苏金单抗”）可提供快速、强有力的皮肤 ...

近日消息，诺华畅销药Cosentyx（司库奇尤单抗）获得美国FDA批准新适应症，用于治疗12岁及以上患有中度至重度化脓性汗腺炎（HS）的儿童患者。诺华在新闻稿中指出，Cosentyx是唯一获批用于该人群的IL-17A抑制剂，也是近十年来首个作用机制不同的IL-17A抑制剂。

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...

Data from the Phase III ECLIPSE head-to-head trial for Johnson & Johnson’s (J&J) interleukin 23 (IL-23) inhibitor Tremfya (guselkumab) in psoriasis patients showed that Tremfya was more effective than ...

Novartis NVS announced that the FDA approved a label expansion of psoriasis drug Cosentyx. The regulatory body approved the drug for treating pediatric patients 12 years and older with moderate to ...

EAST HANOVER, N.J., Feb. 16, 2018 /PRNewswire/ -- Novartis announced today additional results from the SCULPTURE study showing that two thirds of moderate to severe plaque psoriasis patients treated ...

cosentyx article Cosentyx is the first and only fully-human interleukin-17A (IL-17A) antagonist. In the SCALP study, patients with moderate to severe psoriasis lesions of the scalp (n=102) were ...

Basel, September 10, 2022 — Novartis announced the results from two pivotal, Phase III studies (SUNSHINE and SUNRISE), in which Cosentyx® (secukinumab) demonstrated rapid and sustained relief from the ...

Novartis NVS has announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) adopted a positive opinion for the label expansion of blockbuster ...

The FDA has approved Cosentyx® (secukinumab; Novartis) for the treatment of adults with active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. The Food and ...

FDA approval based on robust Phase III data in which Cosentyx ® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 2 1 As the only IL-17A inhibitor ...

Core net income rose to $2.99 billion while sales rose 9% to $12.4 billion. For 2020, the Swiss drugmaker expects net sales to grow in the mid-to high-single-digit percentage range, with core ...